202 related articles for article (PubMed ID: 23137018)
21. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma.
Brundler MA; Harrison JA; de Saussure B; de Perrot M; Pepper MS
J Clin Pathol; 2006 Feb; 59(2):191-5. PubMed ID: 16443737
[TBL] [Abstract][Full Text] [Related]
22. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and recognition of early esophageal neoplasia.
Herszényi L; Pregun I; Tulassay Z
Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
[TBL] [Abstract][Full Text] [Related]
24. [Barrett's esophagus].
Neuhaus H
Praxis (Bern 1994); 2004 Nov; 93(47):1951-7. PubMed ID: 15656005
[TBL] [Abstract][Full Text] [Related]
25. Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors.
Kim NK; Ahn JY; Song J; Kim JK; Han JH; An HJ; Chung HM; Joo JY; Choi JU; Lee KS; Roy R; Oh D
Anticancer Res; 2003; 23(2B):1417-23. PubMed ID: 12820404
[TBL] [Abstract][Full Text] [Related]
26. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
[TBL] [Abstract][Full Text] [Related]
27. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.
Younes M; Brown K; Lauwers GY; Ergun G; Meriano F; Schmulen AC; Barroso A; Ertan A
Histopathology; 2017 Jul; 71(1):27-33. PubMed ID: 28226185
[TBL] [Abstract][Full Text] [Related]
28. Chronology of the Barrett's metaplasia-dysplasia-carcinoma sequence.
Theisen J; Nigro JJ; DeMeester TR; Peters JH; Gastal OL; Hagen JA; Hashemi M; Bremner CG
Dis Esophagus; 2004; 17(1):67-70. PubMed ID: 15209744
[TBL] [Abstract][Full Text] [Related]
29. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
30. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma.
Rajendra S; Wang B; Snow ET; Sharma P; Pavey D; Merrett N; Ball MJ; Brain T; Fernando R; Robertson IK
Am J Gastroenterol; 2013 Jul; 108(7):1082-93. PubMed ID: 23588239
[TBL] [Abstract][Full Text] [Related]
31. Karyometry in Barrett's esophagus.
da Silva VD; Prolla JC; Sharma P; Sampliner R; Thompson D; Bartels PH
Anal Quant Cytol Histol; 2001 Feb; 23(1):40-6. PubMed ID: 11233742
[TBL] [Abstract][Full Text] [Related]
32. The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma.
Li Y; Woodall C; Wo JM; Zheng H; Ng CK; Ray MB; Martin RC
Cancer Invest; 2008; 26(3):278-85. PubMed ID: 18317969
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
[TBL] [Abstract][Full Text] [Related]
34. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
35. Aurora kinase A in Barrett's carcinogenesis.
Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
[TBL] [Abstract][Full Text] [Related]
36. [Barrett's esophagus: diagnosis and therapy].
Schmassmann A; Gebbers JO
Praxis (Bern 1994); 2005 May; 94(21):861-8. PubMed ID: 15966485
[TBL] [Abstract][Full Text] [Related]
37. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
38. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
39. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
40. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
